No connection

Search Results

ARQT vs HAE

ARQT
Arcutis Biotherapeutics, Inc.
BEARISH
Price
$22.75
Market Cap
$2.82B
Sector
Healthcare
AI Confidence
85%
HAE
Haemonetics Corporation
BULLISH
Price
$60.48
Market Cap
$2.81B
Sector
Healthcare
AI Confidence
82%

Valuation

P/E Ratio
ARQT
--
HAE
16.66
Forward P/E
ARQT
17.79
HAE
11.43
P/B Ratio
ARQT
14.81
HAE
3.11
P/S Ratio
ARQT
7.5
HAE
2.13
EV/EBITDA
ARQT
-359.13
HAE
10.06

Profitability

Gross Margin
ARQT
90.24%
HAE
60.21%
Operating Margin
ARQT
14.2%
HAE
21.01%
Profit Margin
ARQT
-4.29%
HAE
13.31%
ROE
ARQT
-9.3%
HAE
19.3%
ROA
ARQT
-1.96%
HAE
6.45%

Growth

Revenue Growth
ARQT
81.5%
HAE
-2.7%
Earnings Growth
ARQT
--
HAE
28.4%

Financial Health

Debt/Equity
ARQT
0.6
HAE
1.34
Current Ratio
ARQT
3.17
HAE
1.75
Quick Ratio
ARQT
2.83
HAE
1.04

Dividends

Dividend Yield
ARQT
--
HAE
--
Payout Ratio
ARQT
0.0%
HAE
0.0%

AI Verdict

ARQT BEARISH

ARQT's Piotroski F-Score of 1/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and no dividend, signaling poor operational health. Despite strong revenue growth of 81.5% YoY and a forward P/E of 17.79, the company remains unprofitable with a negative profit margin of -4.29% and no intrinsic value or Graham Number available. Insider selling totaling $5.12M in the last six months, including significant sales by the CEO and directors, reinforces bearish sentiment. The stock trades at a premium to its fundamentals, with a Price/Sales of 7.50 and Price/Book of 14.81, suggesting overvaluation relative to earnings and book value. Analysts' strong_buy consensus appears disconnected from the underlying financial deterioration.

Strengths
81.5% YoY revenue growth indicates strong market expansion and product demand
High gross margin of 90.24% reflects efficient production and pricing power
Strong current and quick ratios (3.17 and 2.83) suggest solid short-term liquidity
Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and operational instability
Negative ROE (-9.30%) and ROA (-1.96%) indicate poor capital efficiency and unprofitability
Insider selling of $5.12M in 6 months, including CEO and directors, raises governance concerns
HAE BULLISH

HAE exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating a robust financial trajectory. While the stock is currently trading above its Graham Number ($39.87), it remains significantly undervalued relative to its growth-based intrinsic value ($107.08) and a PEG ratio of 0.92. Despite a bearish technical trend and slight revenue contraction (-2.70%), the company demonstrates exceptional operational efficiency with 28.4% earnings growth and a consistent track record of beating EPS estimates. The divergence between strong internal fundamentals and poor price performance suggests a value opportunity.

Strengths
Strong Piotroski F-Score (7/9) signaling high financial health
Attractive valuation with a PEG ratio of 0.92 and Forward P/E of 11.43
Exceptional earnings growth (28.4% YoY) and consistent EPS beats
Risks
Negative revenue growth (-2.70% YoY) indicating top-line stagnation
Bearish technical trend (0/100) suggesting lack of immediate market momentum
Moderate leverage with a Debt/Equity ratio of 1.34

Compare Another Pair

ARQT vs HAE: Head-to-Head Comparison

This page compares Arcutis Biotherapeutics, Inc. (ARQT) and Haemonetics Corporation (HAE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile